Hepatocellular carcinoma and model for end-stage liver disease exceptions: The more we understand, the more challenging the allocation gets

Liver Transplantation

Volumn 18, Issue 4, 2012, Pages 381-383

  Northup, Patrick G ^a   Berg, Carl L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE DUCT CARCINOMA; CYSTIC FIBROSIS; EDITORIAL; FAMILIAL AMYLOID POLYNEUROPATHY; HEPATOPULMONARY SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; PATIENT SELECTION; WAITING LISTS;

EID: 84859297019     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23409     Document Type: Editorial

References (8)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011. http://www.srtr.org/annual-reports/2010/
2. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:1342-1351. (Pubitemid 351615357)
3. Goldberg D, French B, Abt P, Feng S, Cameron AM. Increasing disparity in wait-list mortality rates with increased Model for End-Stage Liver Disease Scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 2012;18:434-443.
4. Organ Procurement and Transplantation Network. Health Resources and Services Administration, HHS. Final rule. Fed Regist 1999;64:56650-56661.
5. Committee on Organ Procurement Transplantation Policy, Institute of Medicine. Organ Procurement and Transplantation: Assessing Current Policies and the Potential Impact of the DHHS Final Rule. Washington, DC: National Academies Press; 1999.
6. Argo CK, Stukenborg GJ, Schmitt TM, Kumer SC, Berg CL, Northup PG. Regional variability in symptom-based MELD exceptions: a response to organ shortage? Am J Transplant 2011;11:2353-2361.
7. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011;11:2362-2371.
8. Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010;10:1643-1648.